DongKoo Bio & Pharma Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 3/6
DongKoo Bio & Pharma has a total shareholder equity of ₩112.6B and total debt of ₩67.8B, which brings its debt-to-equity ratio to 60.2%. Its total assets and total liabilities are ₩225.6B and ₩113.1B respectively. DongKoo Bio & Pharma's EBIT is ₩13.5B making its interest coverage ratio 7.3. It has cash and short-term investments of ₩23.5B.
Anahtar bilgiler
60.2%
Borç/özkaynak oranı
₩67.79b
Borç
| Faiz karşılama oranı | 7.3x |
| Nakit | ₩23.50b |
| Eşitlik | ₩112.57b |
| Toplam yükümlülükler | ₩113.07b |
| Toplam varlıklar | ₩225.64b |
Son finansal sağlık güncellemeleri
Güncelleme yok
Recent updates
More Unpleasant Surprises Could Be In Store For DongKoo Bio & Pharma Co., Ltd.'s (KOSDAQ:006620) Shares After Tumbling 32%
Aug 23
Should You Be Adding DongKoo Bio & Pharma (KOSDAQ:006620) To Your Watchlist Today?
Jul 25We Think That There Are Issues Underlying DongKoo Bio & Pharma's (KOSDAQ:006620) Earnings
Mar 27Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: A006620's short term assets (₩91.7B) do not cover its short term liabilities (₩98.4B).
Uzun Vadeli Yükümlülükler: A006620's short term assets (₩91.7B) exceed its long term liabilities (₩14.6B).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: A006620's net debt to equity ratio (39.4%) is considered satisfactory.
Borcun Azaltılması: A006620's debt to equity ratio has increased from 29.3% to 60.2% over the past 5 years.
Borç Kapsamı: A006620's debt is not well covered by operating cash flow (17.3%).
Faiz Kapsamı: A006620's interest payments on its debt are well covered by EBIT (7.3x coverage).